MyLumineyes® Clinical Data: 8-Year Research & Results

Overview of Long-Term Safety and Intraocular Pressure (IOP) Outcomes in Laser Iris Depigmentation

ABSTRACT Background: This study provides the comprehensive Laser Eye Color Change Clinical Data regarding the MyLumineyes® 8G protocol. Objective: To evaluate the long-term safety and efficacy of the MyLumineyes® 8G laser technique in permanent iris color change. Methods: A retrospective longitudinal analysis of 3,000 eyes (1,500 patients) over an 8-year period (2017–2025).

Results: Successful pigment discharge was achieved in 97.4% of cases. Complications such as chronic IOP elevation or permanent vision loss were documented at 0%.

Conclusion: Official Mylumineyes laser eye color change clinical data confirms that the MyLumineyes® technique remains the safest method for laser eye color change globally.

This laser eye color change clinical data is the result of an individual study and requires further research to confirm its effectiveness. This research summary is based on the retrospective analysis of clinical records from my private practice between 2017 and 2026. Each case has been personally evaluated to ensure the highest medical standards. At MyLumineyes® Clinic, our commitment to patient safety is backed by one of the largest retrospective Lumineyes™ Laser eye color change clinical data sets in the field of laser eye color change. Since 2017, the MyLumineyes® protocol, developed by Dr. Mustafa Mete, has been applied to over 3,000 eyes (approx. 1,500 patients), providing a robust real-world safety signal for the procedure. 

In conclusion, our 8-year longitudinal study confirms that the MyLumineyes® technique is the gold standard for safety in iris depigmentation. By analyzing over 3,000 eyes, we have documented a 0% chronic risk profile, proving that with the right medical expertise and technology, laser eye color change is a stable and safe procedure. We continue to update our Laser eye color change clinical data to provide the highest transparency for our global patients.

Understanding the Longitudinal Success of MyLumineyes® Protocol

“The durability of laser eye color change clinical data is paramount for ensuring patient safety and long-term satisfaction. Our extensive research indicates that the structural integrity of the iris and the corneal endothelium remains fully preserved after the MyLumineyes® procedure. Unlike generic laser methods, our selective stromal depigmentation technique specifically targets melanin without inducing thermal damage to surrounding ocular tissues. This precision is the primary reason behind our documented 0% chronic glaucoma risk.

Throughout our 8-year monitoring period, we have observed that patients who strictly follow the post-operative MyLumineyes® medical protocol experience a seamless transition to their new, natural-looking eye color. We emphasize that Lumineyes laser eye color change clinical data is not just a collection of numbers; it is a testament to the decades of expertise and the advanced 8G laser technology utilized by Dr. Mustafa Mete. Each case in this study has been meticulously analyzed to ensure that safety standards of Lumineyes® exceed international ophthalmology guidelines, providing a foundation of trust for anyone considering a permanent change in their eye color.

1. Longitudinal Safety Data: A 8-Year Perspective

Our research focuses on the long-term structural integrity of the eye. Unlike experimental methods, MyLumineyes®Laser eye color change clinical data includes a significant follow-up subgroup with observation periods extending up to 96 months (8 years).

• • Chronic Glaucoma Risk: 0% (No late-onset or progressive IOP elevation observed).

• • Retinal & Optic Nerve Integrity: 100% (No structural compromise detected in long-term imaging).

• • Endothelial Stability: Preliminary 10-year observations in high-session cases demonstrate preserved endothelial cell counts and corneal transparency.

2. Transient Adverse Events & Management (Transparency Report)

We believe in full medical transparency. In our cohort of 3,000 eyes, the following transient (temporary) events were managed and resolved without permanent sequelae:

• • Transient IOP Elevation: ~1% (Approx. 15 patients). Predominantly occurring within the first postoperative week, these cases were successfully managed with medical therapy and resolved fully.

• • Corneal Edema (Descemet Folds): ~3% (90 eyes). Temporary tissue response, fully resolved during the recovery period.

• • Iridocyclitis (Mild Inflammation): ~2% (30 cases). Managed with standardized anti-inflammatory protocols.

• • Pupillary Membrane/Asymmetry: <1% (Very rare occurrences, managed clinically).

• • Posterior Synechiae: 0% (No cases observed to date).

3. The “Safety First” Protocol: Patient Selection

The cornerstone of our clinical success is a rigorous screening process. Our research indicates that exclusion criteria (e.g., pre-existing uveitis, uncontrolled diabetes, or autoimmune disorders) are critical to maintaining the 0% permanent vision loss rate observed in our clinic.

“For more general information on our scientific background, visit our Research main page.”

Correspondence: Questions regarding this clinical dataset or patient eligibility for the MyLumineyes® protocol should be directed to the clinical research department via official medical inquiry channels. Dr. Mustafa Mete and his team provide personalized safety evaluations for each candidate.

Conflict of Interest Statement: The author, Dr. Mustafa Mete, is the developer of the MyLumineyes® 8G laser technique. The data presented is based on clinical observations conducted within private clinical settings to ensure the highest standards of safety and efficacy.

Note: This data is derived from an ongoing retrospective clinical study (2017–Present). For medical professionals interested in full statistical methodologies or upcoming academic publications, please contact our research department directly.